ClinicalTrials.gg
CompletedNCT02600897Updated Dec 26, 2023Results posted

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 1/2 interventional study of Lenalidomide and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma, sponsored by Hoffmann-La Roche. Completed at 28 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-26.

Primary conditionLymphoma, FollicularRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Follicular
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Follicular.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
114
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing obinutuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 1 of them phase 3. obinutuzumab · Lymphoma, Follicular.

Enrollment
6th of 30
114 · median 49
Started
2016
the only one that year
Phase 1/2
5 of 30
none open now
Registered
8th of 30
by date
Lead sponsor
3 of 30
Hoffmann-La Roche

Among the 30 studies testing obinutuzumab in Lymphoma, Follicular, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 1/2, and was the 8th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

8 of the 30 studies testing obinutuzumab in Lymphoma, Follicular are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing obinutuzumab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and lenalidomide in participants with relapsed or refractory (R/R) follicular lymphoma (FL) and rituximab in combination with polatuzumab vedotin and lenalidomide in participants with R/R diffuse large B-cell lymphoma (DLBCL), followed by post-induction treatment with obinutuzumab in combination with lenalidomide in participants with FL who achieve a complete response (CR), partial response (PR), or stable disease (SD) at end of induction (EOI) and post-induction treatment with rituximab plus lenalidomide in participants with DLBCL who achieve a CR or PR at EOI.

03

Conditions studied

  • Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Browse trials for

04

In context

Lymphoma, Follicular Reclassified

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

This study's enrollment of 114 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to (>/=) 18 years
  • (ECOG) performance status of 0, 1, or 2
  • For obinutuzumab in combination with polatuzumab vedotin and lenalidomide (G + Pola + Len) treatment group: R/R FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator
  • For rituximab in combination with polatuzumab vedotin and lenalidomide (R + Pola + Len) treatment group: R/R DLBCL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody in patients who are not eligible for stem-cell transplantation or who have experienced disease progression following treatment with high-dose chemotherapy plus autologous stem-cell transplantation
  • documented CD20-positive B-cell lymphoma as determined by the local laboratory
  • fluorodeoxyglucose (FDG)-avid lymphoma (i.e., positron emission tomography (PET)-positive lymphoma)
  • At least one bi-dimensionally
  • Agreement to remain abstinent or use adequate , among women or men of

Exclusion criteria

Exclusion Criteria:

  • Grade 3b follicular lymphoma
  • History of transformation of indolent disease to diffuse large B-cell lymphoma (DLBCL)
  • Known CD20-negative status at relapse or progression
  • Central nervous system (CNS) lymphoma or infiltration
  • Prior stem-cell transplantation (SCT), or autologous SCT within 100 days prior to Day 1 of Cycle 1
  • Current use of systemic (s), or prior anti-cancer therapy to include: lenalidomide, fludarabine, or alemtuzumab within 12 months; radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1
  • Active infection
  • Positive for (HIV) or or C
  • Receipt of a within 28 days prior to Day 1 of Cycle 1
  • Poor hematologic, renal, or hepatic function
  • Pregnant or lactating women
  • less than (\<) 3 months
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Dose-escalation Cohort: FL

    Participants with R/R FL will receive 6 months of induction treatment with polatuzumab vedotin and lenalidomide at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and lenalidomide when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 24-month maintenance regimen consisting of lenalidomide and obinutuzumab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).

    Drug: Lenalidomide · Drug: Obinutuzumab · Drug: Polatuzumab Vedotin

  • Experimental
    Dose-escalation Cohort: DLBCL

    Participants with R/R DLBCL will receive 6 months of induction treatment with fixed dose of polatuzumab vedotin and rituximab along with dose escalating lenalidomide. Lenalidomide will be administered at escalating doses to identify the recommended Phase 2 dose (RP2D) for lenalidomide. Those who achieve CR and PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 6-month consolidation regimen consisting of lenalidomide and rituximab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).

    Drug: Lenalidomide · Drug: Polatuzumab Vedotin · Drug: Rituximab

  • Experimental
    Expansion Cohort: FL

    Participants with R/R FL who received induction treatment with polatuzumab vedotin and lenalidomide, in addition to obinutuzumab and achieved CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 24-months maintenance regimen consisting of lenalidomide and obinutuzumab for first 12 months followed by obinutuzumab treatment for next 12 months. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.

    Drug: Lenalidomide · Drug: Obinutuzumab

  • Experimental
    Expansion Cohort: DLBCL

    Participants with R/R DLBCL who received induction treatment with polatuzumab vedotin and lenalidomide in addition to rituximab and achieved CR or PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 6-month consolidation regimen consisting of lenalidomide and rituximab. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.

    Drug: Lenalidomide · Drug: Rituximab

Interventions

  • All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.

  • Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.

  • Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.

  • Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Dose-Limiting Toxicities (DLTs)

    A DLT was defined as any one of the following toxicities occurring during the first cycle of treatment and assessed by the investigator as related to study treatment: Any adverse event of any grade that lead to a delay of \> 14 days in the start of the next treatment cycle, Grade 3 or 4 non-hematologic adverse events with few exceptions; increase in hepatic transaminase \> 3 x baseline and an increase in direct bilirubin \> 2 x upper limits of normal (ULN), without any findings of cholestasis or jaundice, or signs of hepatic dysfunction, and in the absence of other contributory factors; hematologic adverse events that met a few protocol specified criteria. DLTs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Percentages have been rounded off to the first decimal point.

    Time frame: Day 1 of Cycle 1 to Day 1 of Cycle 2 (1 cycle = 28 days) in dose-escalation phase

  2. Percentage of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Percentages have been rounded off to the first decimal point.

    Time frame: From study start up to end of study (Up to a maximum of 69 months)

  3. Percentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans

    CR at EOI was assessed by IRC according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

    Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)

Secondary outcomes

  1. Percentage of Participants With CR at EOI, Determined by the Investigator on the Basis of PET-CT Scans

    CR at EOI was assessed by Investigator according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

    Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)

  2. Percentage of Participants With CR at EOI, Determined by the IRC on the Basis of CT Scans Alone

    CR at EOI was determined by IRC according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

    Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)

  3. Percentage of Participants With CR at EOI, Determined by Investigator on the Basis of CT Scans Alone

    CR at EOI was determined by Investigator according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

    Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)

  4. Percentage of Participants With Objective Response (OR) at EOI, Determined by the IRC on the Basis of PET-CT Scans

    OR was defined as percentage of participants with CR or PR as assessed by the IRC according to MLRC. Per MLRC CR based on PET-CT is complete MR in lymph nodes \& ELS with score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake\> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions;no new lesions \& no evidence of FDG-avid disease in bone marrow.Bone marrow is normal by morphology; if indeterminate, IHC negative. Partial response (PR) based on PET-CT was defined as partial MR in lymph nodes \& ELS with score of 4 or 5 with reduced uptake compared with baseline \& residual masses of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). Percentages have been rounded off up to the second decimal point.

    Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (cycle=28 days) (up to approximately 28 weeks)

  5. Percentage of Participants With Objective Response at EOI, Determined by Investigator on the Basis of PET-CT Scans

    OR was defined percentage of participants with CR or PR assessed by the investigator according to MLRC. Per MLRC CR based on PET-CT is complete MR in lymph nodes \& ELS with score of 1, 2, 3 with or without residual mass on 5PS, where 1=no uptake above background 2=uptake ≤ mediastinum 3=uptake\> mediastinum but ≤ liver 4=uptake moderately \> liver 5=uptake markedly higher than liver and/or new lesions;no new lesions \& no evidence of FDG-avid disease in bone marrow.Bone marrow is normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes \& ELS with score of 4 or 5 with reduced uptake compared with baseline \& residual masses of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline(diffuse uptake compatible with reactive changes from chemotherapy allowed). Percentages are rounded off.

    Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)

  6. Percentage of Participants With Objective Response at EOI, Determined by the IRC on the Basis of CT Scans Alone

    OR was defined as the percentage of participants with CR or PR, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in the sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 28 days). Percentages have been rounded off to the first decimal point.

    Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)

  7. Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of CT Scans Alone

    OR was defined as the percentage of participants with CR or PR, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in the sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

    Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)

  8. Percentage of Participants With Best Response of CR or PR, Determined by the Investigator on the Basis of CT Scans Alone

    BOR=CR/PR per CT per MLRC. Per MLRC, CR based on CT was defined as a complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. Percentages have been rounded off to the first decimal point.

    Time frame: Up to every 6 months until disease progression, unacceptable toxicity or study completion (up to approximately 69 months)

  9. Observed Serum Obinutuzumab Concentration

    1 cycle = 28 days

    Time frame: Day 1 of Cycles 1, 2, 4 & 6: predose & 30 mins postdose; EOI: predose; Day 1 of Maintenance Months 1,7, 13, 19;Day 120 post last dose; one year post last dose; study drug discontinuation; unscheduled visit: predose (up to approximately 69 months)

  10. Observed Serum Rituximab Concentration

    Time frame: Day 1 of Cycles 1, 2, 4, 6: predose and 30 mins post-dose (1 cycle = 28 days) (up to approximately 69 months)

  11. Serum Concentration of Polatuzumab Vedotin Analyte: Total Antibody

    Time frame: Day 1 of Cycles 1, 2, 4: predose (1 cycle = 28 days), Day 120 post last dose; one year post last dose; study drug discontinuation; unscheduled visit: predose (up to approximately 69 months)

  12. Plasma Concentration of Polatuzumab Vedotin Analyte: Antibody-conjugated MMAE (acMMAE)

    Time frame: Day 1 of Cycles 1, 2, 4: predose and 30 mins post-dose; Days 8 and 15 of Cycle 1; Day 1 of Cycle 6: predose, study drug discontinuation; unscheduled visit: predose (1 cycle = 28 days) (up to approximately 69 months)

  13. Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE

    Time frame: Day 1 of Cycles 1, 2, 4: predose and 30 mins post-dose; Days 8 and 15 of Cycle 1 and Day 1 of Cycle 6: predose, study drug discontinuation; unscheduled visit: predose (1 cycle = 28 days) (up to approximately 69 months)

  14. Observed Plasma Lenalidomide Concentration

    Time frame: Day 1 Cycle 1: predose and 2 hours (hr) post-dose; Day 15 Cycle 1: predose, 0.5hr, 1hr, 2hr, 4hr, 8hr post-dose; Day 1 Cycle 6: 2hr post-dose; unscheduled visits: 2hr post-dose (1 cycle = 28 days) (up to approximately 69 months)

  15. Number of Participants With Human Anti-human Antibodies (HAHAs) to Obinutuzumab

    The number of participants with positive results for HAHAs, also called anti-drug antibodies (ADAs) against obinutuzumab at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result.

    Time frame: Baseline up to approximately 2 years after last dose (up to approximately 69 months)

  16. Number of Participants With Human Anti-chimeric Antibodies (HACAs) to Rituximab

    The number of participants with positive results for HACAs, also called ADAs against rituximab at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.

    Time frame: Baseline up to approximately 2 years after last dose (up to approximately 69 months)

  17. Number of Participants With Anti-therapeutic Antibodies (ATAs) to Polatuzumab Vedotin

    The number of participants with positive results for ATAs, also called ADAs against polatuzumab vedotin at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.

    Time frame: Baseline up to approx. 2 years after the last dose of polatuzumab vedotin (up to approximately 30 months)

08

Results

Posted Dec 26, 2023

Participant flow

A total of 114 participants with relapsed or refractory (R/R) follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) were enrolled in this study at 28 investigative sites in Spain, United Kingdom, and United States from 24 March 2016 to 15 December 2021. The study consisted of two phases: dose-escalation and dose-expansion phase. All eligible participants in both phases received induction and post-induction therapy.

Participant flow — Overall Study
MilestoneDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Started343635104040
Intent-to-treat population343635104040
Safety-evaluable population343635104039
Immunogenicity-evaluable population343635103938
Pharmacokinetic-evaluable population343635104039
Completed12240302817
Not completed221232101223
Withdrew: Death12123210720
Withdrew: Lost to follow-up100000010
Withdrew: Withdrawal by subject000000042
Withdrew: Reason not specified000000001

Outcome measures

PrimaryPercentage of Participants With Dose-Limiting Toxicities (DLTs)

A DLT was defined as any one of the following toxicities occurring during the first cycle of treatment and assessed by the investigator as related to study treatment: Any adverse event of any grade that lead to a delay of \> 14 days in the start of the next treatment cycle, Grade 3 or 4 non-hematologic adverse events with few exceptions; increase in hepatic transaminase \> 3 x baseline and an increase in direct bilirubin \> 2 x upper limits of normal (ULN), without any findings of cholestasis or jaundice, or signs of hepatic dysfunction, and in the absence of other contributory factors; hematologic adverse events that met a few protocol specified criteria. DLTs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Percentages have been rounded off to the first decimal point.

Time frame:
Day 1 of Cycle 1 to Day 1 of Cycle 2 (1 cycle = 28 days) in dose-escalation phase
Reported as:
Number · percentage of participants
Percentage of Participants With Dose-Limiting Toxicities (DLTs)
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With Dose-Limiting Toxicities (DLTs)0.050.00.00.00.00.00.0
PrimaryPercentage of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Percentages have been rounded off to the first decimal point.

Time frame:
From study start up to end of study (Up to a maximum of 69 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With Adverse Events (AEs)100.0100.0100.0100.0100.0100.0100.0100.097.4
PrimaryPercentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans

CR at EOI was assessed by IRC according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

Time frame:
6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans66.7 (27.13 to 93.72)0.0 (0.0 to 25.89)60.0 (45.78 to 73.06)38.5 (25.41 to 52.89)
SecondaryPercentage of Participants With CR at EOI, Determined by the Investigator on the Basis of PET-CT Scans

CR at EOI was assessed by Investigator according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

Time frame:
6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With CR at EOI, Determined by the Investigator on the Basis of PET-CT Scans
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With CR at EOI, Determined by the Investigator on the Basis of PET-CT Scans66.7 (27.13 to 93.72)0.0 (0.0 to 25.89)60.0 (45.78 to 73.06)33.3 (20.97 to 47.69)
SecondaryPercentage of Participants With CR at EOI, Determined by the IRC on the Basis of CT Scans Alone

CR at EOI was determined by IRC according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

Time frame:
6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With CR at EOI, Determined by the IRC on the Basis of CT Scans Alone
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With CR at EOI, Determined by the IRC on the Basis of CT Scans Alone16.7 (0.85 to 58.18)0.0 (0.0 to 31.23)31.4 (18.73 to 46.61)12.5 (4.38 to 26.36)
SecondaryPercentage of Participants With CR at EOI, Determined by Investigator on the Basis of CT Scans Alone

CR at EOI was determined by Investigator according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

Time frame:
6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With CR at EOI, Determined by Investigator on the Basis of CT Scans Alone
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With CR at EOI, Determined by Investigator on the Basis of CT Scans Alone16.7 (0.85 to 58.18)0.0 (0.0 to 28.31)29.7 (17.65 to 44.38)28.1 (15.53 to 43.94)
SecondaryPercentage of Participants With Objective Response (OR) at EOI, Determined by the IRC on the Basis of PET-CT Scans

OR was defined as percentage of participants with CR or PR as assessed by the IRC according to MLRC. Per MLRC CR based on PET-CT is complete MR in lymph nodes \& ELS with score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake\> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions;no new lesions \& no evidence of FDG-avid disease in bone marrow.Bone marrow is normal by morphology; if indeterminate, IHC negative. Partial response (PR) based on PET-CT was defined as partial MR in lymph nodes \& ELS with score of 4 or 5 with reduced uptake compared with baseline \& residual masses of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). Percentages have been rounded off up to the second decimal point.

Time frame:
6 to 8 weeks after Day 1 of Cycle 6 (cycle=28 days) (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR) at EOI, Determined by the IRC on the Basis of PET-CT Scans
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With Objective Response (OR) at EOI, Determined by the IRC on the Basis of PET-CT Scans100.0 (60.70 to 100.0)10.0 (0.51 to 39.42)72.50 (58.61 to 83.75)46.20 (32.35 to 60.42)
SecondaryPercentage of Participants With Objective Response at EOI, Determined by Investigator on the Basis of PET-CT Scans

OR was defined percentage of participants with CR or PR assessed by the investigator according to MLRC. Per MLRC CR based on PET-CT is complete MR in lymph nodes \& ELS with score of 1, 2, 3 with or without residual mass on 5PS, where 1=no uptake above background 2=uptake ≤ mediastinum 3=uptake\> mediastinum but ≤ liver 4=uptake moderately \> liver 5=uptake markedly higher than liver and/or new lesions;no new lesions \& no evidence of FDG-avid disease in bone marrow.Bone marrow is normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes \& ELS with score of 4 or 5 with reduced uptake compared with baseline \& residual masses of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline(diffuse uptake compatible with reactive changes from chemotherapy allowed). Percentages are rounded off.

Time frame:
6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response at EOI, Determined by Investigator on the Basis of PET-CT Scans
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With Objective Response at EOI, Determined by Investigator on the Basis of PET-CT Scans100.0 (60.70 to 100.0)10.0 (0.51 to 39.42)80.0 (66.80 to 89.64)46.20 (32.35 to 60.42)
SecondaryPercentage of Participants With Objective Response at EOI, Determined by the IRC on the Basis of CT Scans Alone

OR was defined as the percentage of participants with CR or PR, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in the sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 28 days). Percentages have been rounded off to the first decimal point.

Time frame:
6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response at EOI, Determined by the IRC on the Basis of CT Scans Alone
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With Objective Response at EOI, Determined by the IRC on the Basis of CT Scans Alone100.0 (60.70 to 100.0)12.5 (0.64 to 47.07)91.4 (79.31 to 97.62)53.1 (37.34 to 68.46)
SecondaryPercentage of Participants With Objective Response, Determined by the Investigator on the Basis of CT Scans Alone

OR was defined as the percentage of participants with CR or PR, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in the sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.

Time frame:
6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of CT Scans Alone
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of CT Scans Alone100.0 (60.70 to 100.0)11.1 (0.57 to 42.91)89.2 (76.95 to 96.22)59.4 (43.35 to 74.03)
SecondaryPercentage of Participants With Best Response of CR or PR, Determined by the Investigator on the Basis of CT Scans Alone

BOR=CR/PR per CT per MLRC. Per MLRC, CR based on CT was defined as a complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. Percentages have been rounded off to the first decimal point.

Time frame:
Up to every 6 months until disease progression, unacceptable toxicity or study completion (up to approximately 69 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Response of CR or PR, Determined by the Investigator on the Basis of CT Scans Alone
percentage of participantsDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Percentage of Participants With Best Response of CR or PR, Determined by the Investigator on the Basis of CT Scans Alone100.0 (60.70 to 100.0)50.0 (22.24 to 77.76)90.0 (78.56 to 96.51)79.5 (66.02 to 89.36)
SecondaryObserved Serum Obinutuzumab Concentration

1 cycle = 28 days

Time frame:
Day 1 of Cycles 1, 2, 4 & 6: predose & 30 mins postdose; EOI: predose; Day 1 of Maintenance Months 1,7, 13, 19;Day 120 post last dose; one year post last dose; study drug discontinuation; unscheduled visit: predose (up to approximately 69 months)
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Observed Serum Obinutuzumab Concentration
micrograms per milliliter (μg/mL)Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL
Induction Cycle 1 Day 1 / PredoseNA ± NANA ± NANA ± NANA ± NANA ± NA
Induction Cycle 1 Day 1 / 30 mins394 ± 22.1358 ± 20.5351 ± 15.2333 ± 70.0182 ± 206.7
Induction Cycle 2 Day 1 / Predose451 ± 23.5372 ± 37.0386 ± 4.6481 ± 23.1312 ± 40.8
Induction Cycle 2 Day 1 / 30 mins830 ± 38.3749 ± 17.2695 ± 14.3667 ± 77.5588 ± 41.4
Induction Cycle 4 Day 1 / Predose354 ± 15.0321 ± 43.6344 ± 13.4405 ± 24.9270 ± 41.8
Induction Cycle 4 Day 1 / 30 mins103 ± NA644 ± 42.8653 ± 20.6742 ± 27.8547 ± 37.1
Induction Cycle 6 Day 1 / Predose255 ± 36.6504 ± NA327 ± 5.8384 ± 52.2255 ± 49.0
Induction Cycle 6 Day 1 / 30 mins730 ± 15.5804 ± NA1.18 ± NA751 ± 35.3543 ± 36.2
EOI / Predose108 ± 32.6————
Maintenance Month 1 / Predose231 ± 19.1381 ± NA—230 ± 87.4176 ± 60.1
Maintenance Month 7 / Predose128 ± NA212 ± NA229 ± NA125 ± 143.7135 ± 64.3
Maintenance Month 13 / Predose—142 ± NA269 ± NA134 ± 105.3150 ± 70.7
Maintenance Month 19 / Predose—354 ± NA204 ± NA154 ± 144.1165 ± 59.5
Study Drug Discontinuation—46.4 ± NA—17.3 ± NA87.5 ± 588.7
Day 120 Post Last Dose29.1 ± NA———44.5 ± 806.5
1 Year Post Last Dose——0.377 ± NA—0.340 ± 955.9
Unscheduled / Predose————561 ± NA
SecondaryObserved Serum Rituximab Concentration
Time frame:
Day 1 of Cycles 1, 2, 4, 6: predose and 30 mins post-dose (1 cycle = 28 days) (up to approximately 69 months)
Reported as:
Geometric mean · μg/mL
Observed Serum Rituximab Concentration
μg/mLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Induction Cycle 1 Day 1 / PredoseNA ± NANA ± NANA ± NANA ± NA
Induction Cycle 1 Day 1 / 30 mins151 ± 42.9203 ± 28.1175 ± 18.7174 ± 45.4
Induction Cycle 2 Day 1 / Predose25.6 ± 78.033.3 ± 43.731.7 ± 26.226.4 ± 73.4
Induction Cycle 2 Day 1 / 30 mins133 ± NA172 ± NA222 ± NA194 ± 36.4
Induction Cycle 4 Day 1 / Predose20.4 ± NA74.6 ± 33.853.1 ± 43.758.3 ± 44.4
Induction Cycle 4 Day 1 / 30 mins159 ± NA224 ± 5.7220 ± 16.2228 ± 36.6
Induction Cycle 6 Day 1 / Predose15.3 ± NA79.5 ± 42.374.7 ± 22.168.9 ± 60.6
Induction Cycle 6 Day 1 / 30 mins135 ± NA250 ± 7.6233 ± 1.8256 ± 26.4
SecondarySerum Concentration of Polatuzumab Vedotin Analyte: Total Antibody
Time frame:
Day 1 of Cycles 1, 2, 4: predose (1 cycle = 28 days), Day 120 post last dose; one year post last dose; study drug discontinuation; unscheduled visit: predose (up to approximately 69 months)
Reported as:
Geometric mean · μg/mL
Serum Concentration of Polatuzumab Vedotin Analyte: Total Antibody
μg/mLDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Induction Cycle 1 Day 1 / PredoseNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Induction Cycle 2 Day 1 / Predose1.47 ± 16.22.01 ± 51.10.200 ± 958.30.622 ± 152.81.57 ± 62.91.61 ± 59.81.47 ± 26.20.339 ± 391.81.35 ± 122.0
Induction Cycle 4 Day 1 / Predose1.83 ± 51.74.45 ± 20.52.57 ± 30.52.12 ± 69.00.900 ± NA2.96 ± 44.43.10 ± 43.62.31 ± 48.53.42 ± 46.1
Study Drug Discontinuation0.106 ± 209.10.170 ± NA—0.0903 ± NA1.50 ± NA6.16 ± NA3.25 ± 49.70.175 ± NA0.455 ± 448.4
Day 120 Post Last Dose0.0661 ± NA————0.208 ± NA0.107 ± NA0.0365 ± NA0.0666 ± NA
1 Year Post Last Dose0.0250 ± NA—0.0250 ± NA————0.0357 ± NA0.0250 ± NA
Unscheduled / Predose————————2.59 ± NA
SecondaryPlasma Concentration of Polatuzumab Vedotin Analyte: Antibody-conjugated MMAE (acMMAE)
Time frame:
Day 1 of Cycles 1, 2, 4: predose and 30 mins post-dose; Days 8 and 15 of Cycle 1; Day 1 of Cycle 6: predose, study drug discontinuation; unscheduled visit: predose (1 cycle = 28 days) (up to approximately 69 months)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Plasma Concentration of Polatuzumab Vedotin Analyte: Antibody-conjugated MMAE (acMMAE)
nanograms per milliliter (ng/mL)Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Induction Cycle 1 Day 1 / PredoseNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Induction Cycle 1 Day 1 / 30 mins580 ± 41.6660 ± 24.7476 ± 16.0432 ± 27.9568 ± 27.7106 ± 60902.6513 ± 73.5333 ± 267.2522 ± 323.0
Induction Cycle 1 Day 850.2 ± 7.380.0 ± 17.611.4 ± 232.227.7 ± 69.258.9 ± 44.452.0 ± 36.343.9 ± 96.411.9 ± 799.056.6 ± 90.2
Induction Cycle 1 Day 1517.3 ± 5.524.7 ± 13.82.50 ± 483.16.73 ± 118.822.3 ± 31.218.3 ± 48.718.6 ± 30.55.95 ± 366.116.9 ± 118.6
Induction Cycle 2 Day 1 / Predose4.96 ± 21.36.55 ± 58.70.961 ± 477.52.50 ± 119.87.44 ± 40.25.58 ± 77.26.12 ± 18.11.88 ± 490.25.32 ± 103.6
Induction Cycle 2 Day 1 / 30 mins555 ± 15.8623 ± 18.4508 ± 22.7295 ± 174.6537 ± 40.3568 ± 14.1716 ± 16.5481 ± 54.3451 ± 391.7
Induction Cycle 4 Day 1 / Predose5.34 ± 73.911.5 ± NA8.47 ± 19.57.68 ± 60.84.19 ± NA8.25 ± 59.411.7 ± 74.28.99 ± 36.711.3 ± 45.2
Induction Cycle 4 Day 1 / 30 mins32.9 ± 101980.7416 ± 87.7519 ± 9.3531 ± 17.6371 ± NA507 ± 42.8737 ± 20.8492 ± 22.3645 ± 107.2
Induction Cycle 6 Day 1 / Predose7.70 ± 26.019.9 ± NA9.37 ± 42.69.70 ± 53.03.06 ± NA11.5 ± 41.615.8 ± 45.49.82 ± 40.411.8 ± 66.0
Study Drug Discontinuation0.180 ± NA0.635 ± NA—0.180 ± NA———1.71 ± 378.4—
Unscheduled / Predose———————23.1 ± 62.59.78 ± NA
SecondaryPlasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
Time frame:
Day 1 of Cycles 1, 2, 4: predose and 30 mins post-dose; Days 8 and 15 of Cycle 1 and Day 1 of Cycle 6: predose, study drug discontinuation; unscheduled visit: predose (1 cycle = 28 days) (up to approximately 69 months)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
ng/mLDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Induction Cycle 1 Day 1 / PredoseNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Induction Cycle 1 Day 1 / 30 mins0.228 ± 7.80.160 ± 69.90.420 ± 100.60.233 ± 74.00.156 ± 62.10.167 ± 214.80.298 ± 198.70.347 ± 327.50.297 ± 111.1
Induction Cycle 1 Day 81.15 ± 34.92.05 ± 49.72.40 ± 102.01.64 ± 135.51.89 ± 76.11.36 ± 29.63.65 ± 75.31.12 ± 227.02.56 ± 144.8
Induction Cycle 1 Day 150.457 ± 56.30.459 ± 54.50.387 ± 6.00.435 ± 129.50.485 ± 204.00.456 ± 39.80.683 ± 63.30.294 ± 170.90.843 ± 125.2
Induction Cycle 2 Day 1 / Predose0.0280 ± NA0.0315 ± NA0.0244 ± NA0.0334 ± NA0.0501 ± 149.00.0310 ± NA0.0527 ± 102.80.0268 ± NA0.0713 ± 125.0
Induction Cycle 2 Day 1 / 30 mins0.151 ± 68.60.138 ± 133.00.151 ± 49.80.136 ± 339.90.186 ± 51.20.123 ± 53.80.157 ± 72.50.102 ± 101.20.210 ± 77.3
Induction Cycle 4 Day 1 / Predose0.0431 ± NA0.117 ± NA0.0672 ± 56.90.0283 ± NA0.0180 ± NA0.0344 ± 61.00.0729 ± 11.40.0366 ± NA0.0776 ± 101.5
Induction Cycle 4 Day 1 / 30 mins0.0817 ± NA0.156 ± 18.70.104 ± 7.10.0752 ± 113.20.0180 ± NA0.133 ± 50.90.208 ± 44.90.102 ± 57.70.213 ± 51.3
Induction Cycle 6 Day 1 / Predose0.0367 ± 68.30.0929 ± NA0.0821 ± 93.80.0267 ± NA0.0180 ± NA0.0517 ± 118.90.0405 ± NA0.0342 ± NA0.0852 ± 62.6
Study Drug Discontinuation0.0180 ± NA0.0180 ± NA—0.0180 ± NA———0.0180 ± NA—
Unscheduled / Predose———————0.180 ± NA0.0180 ± NA
SecondaryObserved Plasma Lenalidomide Concentration
Time frame:
Day 1 Cycle 1: predose and 2 hours (hr) post-dose; Day 15 Cycle 1: predose, 0.5hr, 1hr, 2hr, 4hr, 8hr post-dose; Day 1 Cycle 6: 2hr post-dose; unscheduled visits: 2hr post-dose (1 cycle = 28 days) (up to approximately 69 months)
Reported as:
Geometric mean · ng/mL
Observed Plasma Lenalidomide Concentration
ng/mLDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Induction Cycle 1 Day 1 / PredoseNA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
Induction Cycle 1 Day 1 / 2h118 ± 44.0144 ± 30.3201 ± 54.0305 ± 37.125.2 ± 239.4237 ± 47.4197 ± 184.1306 ± 43.1277 ± 60.0
Induction Cycle 1 Day 15 / Predose5.97 ± 628.00.729 ± 540.08.74 ± 277.05.20 ± 275.15.43 ± 9.12.64 ± 68.08.33 ± 112.09.99 ± 260.910.4 ± 196.4
Induction Cycle 1 Day 15 / 30 min64.0 ± 1553.11.95 ± NA179 ± 220.1202 ± 115.612.5 ± 76.441.7 ± 546.773.3 ± 395.5124 ± 300.394.5 ± 204.9
Induction Cycle 1 Day 15 / 1h61.4 ± 1354.840.8 ± 183.1189 ± 48.0272 ± 48.269.9 ± 10.3224 ± 76.8187 ± 150.5236 ± 147.7245 ± 106.8
Induction Cycle 1 Day 15 / 2h117 ± 53.293.3 ± 40.5202 ± 36.0200 ± 45.5118 ± 22.3232 ± 25.5328 ± 38.2305 ± 53.6242 ± 297.2
Induction Cycle 1 Day 15 / 4h96.4 ± 62.065.7 ± 46.3116 ± 28.9152 ± 36.979.9 ± 28.2134 ± 23.6245 ± 36.3214 ± 41.1205 ± 45.4
Induction Cycle 1 Day 15 / 8h35.0 ± 109.129.2 ± 55.256.8 ± 57.249.8 ± 23.344.0 ± 40.257.0 ± 19.1105 ± 50.9103 ± 56.3103 ± 67.6
Induction Cycle 6 Day 1 / 2h124 ± 21.476.1 ± NA110 ± 35.1227 ± 48.136.2 ± NA258 ± 10.5255 ± 36.5237 ± 52.1153 ± 515.5
Unscheduled / 2h———————199 ± 53.3—
SecondaryNumber of Participants With Human Anti-human Antibodies (HAHAs) to Obinutuzumab

The number of participants with positive results for HAHAs, also called anti-drug antibodies (ADAs) against obinutuzumab at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result.

Time frame:
Baseline up to approximately 2 years after last dose (up to approximately 69 months)
Reported as:
Count of participants · Participants
Number of Participants With Human Anti-human Antibodies (HAHAs) to Obinutuzumab
ParticipantsDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL
Baseline prevalence of ADAs00003
Post baseline incidence of ADAs00000
SecondaryNumber of Participants With Human Anti-chimeric Antibodies (HACAs) to Rituximab

The number of participants with positive results for HACAs, also called ADAs against rituximab at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.

Time frame:
Baseline up to approximately 2 years after last dose (up to approximately 69 months)
Reported as:
Count of participants · Participants
Number of Participants With Human Anti-chimeric Antibodies (HACAs) to Rituximab
ParticipantsDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Baseline prevalence of ADAs0000
Post baseline incidence of ADAs0000
SecondaryNumber of Participants With Anti-therapeutic Antibodies (ATAs) to Polatuzumab Vedotin

The number of participants with positive results for ATAs, also called ADAs against polatuzumab vedotin at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.

Time frame:
Baseline up to approx. 2 years after the last dose of polatuzumab vedotin (up to approximately 30 months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-therapeutic Antibodies (ATAs) to Polatuzumab Vedotin
ParticipantsDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
Baseline prevalence of ADAs000000011
Post baseline incidence of ADAs000000000

Adverse events

Collected over From Baseline up to study completion/discontinuation (maximum of 69 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL1/3 (33.3%)3/3 (100%)3/3 (100%)
Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL2/4 (50%)2/4 (50%)4/4 (100%)
Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL2/6 (33.3%)3/6 (50%)6/6 (100%)
Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL3/3 (100%)0/3 (0%)3/3 (100%)
Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL2/5 (40%)0/5 (0%)5/5 (100%)
Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL10/10 (100%)4/10 (40%)9/10 (90%)
Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL7/40 (17.5%)26/40 (65%)40/40 (100%)
Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL20/39 (51.3%)19/39 (48.7%)37/39 (94.9%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/30/41/30/60/30/50/104/401/39
ACUTE CORONARY SYNDROMECardiac disorders0/30/41/30/60/30/50/100/400/39
COLITISGastrointestinal disorders1/30/40/30/60/30/50/100/400/39
DIARRHOEAGastrointestinal disorders1/30/40/30/60/30/50/100/400/39
PYREXIAGeneral disorders1/30/40/31/60/30/50/102/402/39
SEPTIC SHOCKInfections and infestations0/30/41/30/60/30/50/101/400/39
FEMUR FRACTUREInjury, poisoning and procedural complications1/30/40/30/60/30/50/100/400/39
URINARY TRACT INFECTIONInfections and infestations0/31/40/30/60/30/50/101/400/39
ANKLE FRACTUREInjury, poisoning and procedural complications0/31/40/30/60/30/50/100/400/39
NEUTROPENIABlood and lymphatic system disorders0/30/40/31/60/30/50/100/400/39
Most frequent other events
Showing 10 of 163
Most frequent other events
EventDose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL
NEUTROPENIABlood and lymphatic system disorders1/32/41/36/62/33/57/1026/4025/39
THROMBOCYTOPENIABlood and lymphatic system disorders0/32/41/35/61/31/52/1022/4010/39
DIARRHOEAGastrointestinal disorders2/32/42/31/61/31/52/1017/4013/39
NAUSEAGastrointestinal disorders1/31/42/30/61/30/50/108/405/39
FATIGUEGeneral disorders1/30/42/30/60/31/50/1011/406/39
PYREXIAGeneral disorders2/30/42/33/61/31/51/1013/405/39
RASHSkin and subcutaneous tissue disorders2/31/41/30/60/30/54/105/407/39
ANAEMIABlood and lymphatic system disorders1/30/41/33/61/32/55/1018/4014/39
ASTHENIAGeneral disorders0/32/41/31/61/30/52/107/406/39
BLOOD CREATININE INCREASEDInvestigations0/32/40/31/60/31/50/105/403/39

Baseline characteristics

The ITT population included all participants enrolled in the study.

Age, Continuous
Age, Continuous(years)Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLTotal
Mean61.3 ± 6.172.5 ± 8.156.0 ± 3.558.3 ± 12.059.7 ± 6.562.0 ± 14.961.4 ± 14.261.6 ± 11.268.4 ± 12.864.0 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLTotal
Female2324014121442
Male1112346282672
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLTotal
American Indian or Alaska Native0000000000
Asian0000000112
Native Hawaiian or Other Pacific Islander0000000000
Black or African American0000000000
White343635103638108
More than one race0000000000
Unknown or Not Reported0000000314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FLDose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLDose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCLDose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLExpansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FLExpansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCLTotal
Ethnicity — Hispanic or Latino00000134412
Ethnicity — Not Hispanic or Latino3426347343497
Ethnicity — Not Stated0010000214
Ethnicity — Unknown0000000011
09

Study locations

28 sites
  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
    Marietta, Georgia 30060, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • University of Missouri/Ellis Fischel
    Columbia, Missouri 65212, United States
  • Washington University; Wash Uni. Sch. Of Med
    Saint Louis, Missouri 63110, United States
  • NYU School of Medicine
    New York, New York 10016, United States
  • Rocky Mountain Cancer Centers, LLP
    Irving, Texas 75063, United States
  • Texas Oncology-Tyler
    Irving, Texas 75063, United States
  • Texas Oncology San Antonio Medical Center
    San Antonio, Texas 78240, United States
  • Insititut Catala D'Oncologia
    Hospitalet de Llobregat, Barcelona 08908, Spain
  • Hospital Clínico Málaga
    Málaga, Malaga 29010, Spain
  • Complejo Hospitalario de Navarra
    Pamplona, Navarra 31008, Spain
  • Clínica Universidad de Navarra
    Pamplona, Navarra 31620, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clínic. Barcelona
    Barcelona, 08036, Spain
  • Hospital Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Gregorio Marañon
    Madrid, 28007, Spain
  • H. Universitario Leonor
    Madrid, 28031, Spain
  • Hospital Universitario Fundacion Jimenez Diaz.
    Madrid, 28040, Spain
  • Hospital La Fe
    Valencia, Spain
  • St James University Hospital
    Leeds, LS9 7TF, United Kingdom
  • University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
  • Barts Hospital; Institute of Cancer
    London, EC1M 6BQ, United Kingdom
  • Sarah Cannon Research Institute
    London, W1G 6AD, United Kingdom
  • Maidstone & Tonbridge Wells Hospital; Kent Oncology Center
    Maidstone, ME16 9QQ, United Kingdom
  • Nottingham University Hospitals NHS Trust - City Hospital
    Nottingham, NG5 1PB, United Kingdom
  • Barking, Havering and Redbridge University Hospitals NHS Trust - Queen's Hospital
    Romford, RM7 0AG, United Kingdom
  • The Royal Wolverhampton Hospitals NHS Trust; Department of Haematology
    Wolverhampton, WV10 0QP, United Kingdom
10

References and documents

Publications

  • Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang Y, Paulson JN, Chang YM, Musick L, Abrisqueta P. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematol. 2021 Dec;8(12):e891-e901. doi: 10.1016/S2352-3026(21)00311-2. PubMed 34826412 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Dec 2021, 68 months.

Results were first posted in Dec 2023, 2 years after primary completion.

Of 43 industry-sponsored phase 1/2 interventional studies under Lymphoma, Follicular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 103. This study's 68 months is close to that.

Counting every sponsor, half of 88 studies reached it within 73 months; a quarter within 50 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2015
First posted
Nov 9, 2015
StartActual
Mar 24, 2016
Primary completionActual
Dec 15, 2021
CompletionActual
Dec 15, 2021
Results first posted
Dec 26, 2023
Last update
Dec 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02600897
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 9, 2015
Start date
Mar 24, 2016
Primary completion
Dec 15, 2021
Completion
Dec 15, 2021
Results posted
Dec 26, 2023
Last update
Dec 26, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Obinutuzumab · Polatuzumab vedotin · Rituximab

Start the discussion